Most important clinical trials presented at the HOT LINE sessions of the European Society of Cardiology Congress 2026
The next Congress of the European Society of Cardiology was held in Munich (Germany) from August 28 to 31, 2026. The motto of this year's event is "Research. Innovation. Inspiration." The Congress participants reviewed 4 new texts of clinical recommendations in various fields of cardiology and other fields of medicine.
ACC and AHA updated their recommendations on statins in 2026
Cardiologists have revised the 2018 statin recommendations. After just under 10 years, during which the target indicators were based solely on percentage reduction, clear numerical target levels for low‑density lipoproteins have been re‑established.
New Tool to Guide Transcatheter Aortic Valve Replacement
A new German trigger tool identified adverse events in pediatric cardiology admissions, with most events causing temporary harm. The tool demonstrated good interrater reliability and was feasible for systematic detection of patient harm in hospitalized children.
The release of a new open access journal of cardiology
In August 2026, a group of cardiologists launched the peer—reviewed open access journal OpenSource: Cardiology. The main difference of the publication is the complete absence of publication fees for the authors.
To Beat Cigarette Addiction, Experts Embrace Vapes
Clinicians can now recommend vapes, along with nicotine patches and gums, to their adult patients who want to quit smoking traditional cigarettes. The guidance, from a leading international group of tobacco researchers, represents a sharp pivot from an earlier stance that evolved as evidence mounted that vaping may be more effective in helping people quit cigarettes than traditional nicotine replacement therapies like varenicline or bupropion.
New Guidelines Expand Statin Eligibility to More Than Half of US Adults
A new study has shown that the updated recommendations of the American Heart Association and the American College of Cardiology on dyslipidemia, published in March 2026, expand indications for statin therapy for primary prevention, now covering adults aged 30-79 years (instead of 40-75 years), assessing the risk for several decades ahead and using an updated risk calculator, which will allow such treatment to spread. 87.5 million adults in the United States.
Obesity and CVD: Launching the Heart Foundation's new clinical consensus statement
In Australia, about two-thirds of adults are overweight or obese, placing them at increased risk of cardiovascular disease (CVD) including coronary heart disease, heart failure, and arrhythmias. The Heart Foundation recently launched an Australian-first clinical consensus statement on obesity and CVD.
Simulation deficit in cardiology training: a missed opportunity for the modern trainee
Cardiology training today exists in a paradox. As the specialty becomes more complex, particularly in procedural domains, the time and resources available to train new cardiologists have dwindled. Simulation has become an increasingly important component of modern cardiology training, offering a safe, structured and reproducible environment in which clinical skills can be developed and refined.1 The term simulation encompasses a broad spectrum of educational approaches, ranging from focused task training to high-fidelity scenario-based learning.
Shingles vaccine protects against cardiovascular diseases
Shingles vaccination reduced major adverse cardiac events and secondary cardiovascular outcomes for patients with atherosclerotic cardiovascular disease, according to new research.
Heart failure evidence update 2026
The interval since the 2021 European Society of Cardiology (ESC) Guidelines and 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) Guidelines publications has witnessed an unprecedented volume of evidence that substantially expands the therapeutic landscape across the entire ejection fraction spectrum.
RU
EN